… Botulinum neurotoxins (BoNTs) are toxins produced by the bacteria Clostridium botulinum …
The muscle relaxation induced by BoNTs underlies their use as elective drugs for the therapy …

For more than three decades, Botulinum neurotoxin (BoNT) has been used to treat a variety
of clinical conditions such as spastic or dystonic disorders by inducing a temporary paralysis …

… The therapeutic use of botulinum neurotoxin type A (BoNT/A) in humans is now well … These
drawbacks can be overcome by using a different BoNT serotype and the therapeutic use of …

… The two proteins most largely used in human therapy are the immunoglobulins (Ig) and
the botulinum neurotoxins (BoNTs). Apart from sharing the molecular weight of 150 kDa, they …

… Clostridium botulinum neurotoxins (BoNTs) are the most potent protein toxins for humans
(1). BoNTs elicit neuronal-specific flaccid paralysis by targeting neurons and cleaving neuron-…

… Specific treatment is not available for human botulism. Current remedial mainstay is the
passive administration of polyclonal antibody to botulinum neurotoxin (BoNT) derived from …

… In contrast, the seven serotypes of botulinum neurotoxins (BoNTs) act at the periphery by
inducing a £accid paralysis due to the inhibition of acetylcholine release at the neuromuscular …

The study of botulinum neurotoxins (BoNT) is rapidly progressing in many aspects. Novel …
as therapeutic agents in an ever increasing number of applications, including pain therapy. …

… Botulinum neurotoxin (BoNT) is a major therapeutic agent … overview of the current therapeutic
landscape and explore the … for disease-tailored BoNT therapies. However, there are some …

… The seven botulinum neurotoxin serotypes share less than … when investigation of an outbreak
of botulism in Belgium in 1895 … Among the seven botulinum neurotoxins, type A and type B …